adher-2/neu transduced dendritic cells
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2005 (NCT00162929)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Immunity, active
ERBB2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- adher-2/neu transduced dendritic cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00162929 | Phase 1 | Jan 1, 2005 | Canadian Breast Cancer Research Alliance, McMaster University, Ontario Cancer Research Network |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Canadian Breast Cancer Research Alliance | Academic/Hospital | 1 | 0 | 1 | 2005 |
| McMaster University | Academic/Hospital | 1 | 1 | 1 | 2005 |
| Ontario Cancer Research Network | Academic/Hospital | 1 | 0 | 1 | 2005 |
3 organizations
Page 1 / 1